DINAMIC: Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects

Sponsor

EpicentRx, Inc. (Industry)

Overall Status

Completed

CT.gov ID

NCT01359982

Collaborator

(none)

Enrollment

Locations

Arm

Duration (Months)

Patients Per Site

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety and pharmacokinetic profile of RRx-001 for injection in subjects with advanced solid tumors or lymphomas for which there are no currently accepted curative therapies. This study will also conduct an exploratory evaluation of objective tumor response using CT or MRI.

Condition or Disease	Intervention/Treatment	Phase
Malignant Solid Tumor Lymphomas	Drug: RRx-001 Drug: RRx-001 Drug: RRx-001 Drug: RRx-001 Drug: RRx-001 Drug: RRx-001	Phase 1

Detailed Description

The DINAMIC (DINitroazetidines As Medications In Cancer) trial represents a provascular approach to temporarily change tumor blood flow and oxygenation. Blood supply to most tumors is poor, causing parts of tumors to have a low oxygen content which promotes aggressiveness and metastasis. The DINAMIC trial uses specific imaging techniques (including ultrasound), biopsy, and breath analysis to provide an early assessment of therapeutic activity.

Study Design

Study Type:

Interventional

Actual Enrollment :

26 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of RRx-001 in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Curative Therapies

Study Start Date :

Sep 1, 2011

Actual Primary Completion Date :

Feb 1, 2015

Actual Study Completion Date :

Feb 1, 2015

Arms and Interventions

Arm	Intervention/Treatment
Experimental: RRx-001	Drug: RRx-001 Dose level 1 (10 mg/m2) Drug: RRx-001 Dose Level 2 (16.7 mg/m2) Drug: RRx-001 Dose Level 3 (24.6 mg/m2) Drug: RRx-001 Dose Level 4 (33 mg/m2) Drug: RRx-001 Dose Level 5 (55.0 mg/m2) Drug: RRx-001 Dose Level 6 (83 mg/m2)

Arm

Intervention/Treatment

Experimental: RRx-001

Drug: RRx-001

Dose level 1 (10 mg/m2)

Drug: RRx-001

Dose Level 2 (16.7 mg/m2)

Drug: RRx-001

Dose Level 3 (24.6 mg/m2)

Drug: RRx-001

Dose Level 4 (33 mg/m2)

Drug: RRx-001

Dose Level 5 (55.0 mg/m2)

Drug: RRx-001

Dose Level 6 (83 mg/m2)

Outcome Measures

Primary Outcome Measures

Number, frequency and type of adverse events [92 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Subject is male or female, aged at least 18 years.
Subject has a histologically or cytologically confirmed diagnosis of an advanced, malignant, incurable solid tumor(s) or lymphoma that is metastatic and/or unresectable and/or for which standard curative measures either are not applicable, or do not exist, or are no longer effective. Subjects with curative treatment options are not eligible for the protocol.
Subject is not receiving any active treatment for his/her malignancy (except for prostate cancer subjects receiving luteinizing hormone-releasing hormone (LHRH) agonists and antiandrogens such as: Flutamide, Dutasteride, and Finasteride).
Subject's Eastern Cooperative Group (ECOG) performance status is 0, 1 or 2 at Screening.
Subject has acceptable liver function at Screening
Subject has a normal serum creatinine.
Subject has acceptable hematologic status at Screening
Female subjects of childbearing potential (i.e., women who have not been surgically sterilized or have not been post-menopausal for at least one year), and male subjects with partners of childbearing potential, must agree to use medically acceptable methods of contraception beginning on Study Day 1 and continuing until at least four weeks after administration of the subject's final dose of RRx-001.

Exclusion Criteria:

Impaired cardiac function that in the opinion of the Investigator could interfere with the conduct of the study or could put the subject at unacceptable risk.
Right-to-left, bidirectional, or transient right-to-left cardiac shunts.
Subjects with a history of acute cerebral infarction or transient ischemic attack within 90 days prior to Study Day 1.
Acute myocardial infarction or acute coronary syndromes less than one year prior to enrollment.
Serious ventricular arrythmias or high risk for arrhythmias due to prolongation of the QT interval.
Subjects who experienced a major surgery, radiotherapy, or immunotherapy within the last 21 days prior to Study Day 1 (limited palliative radiation is allowed within 14 days prior to Study Day 1).
Chemotherapy regimens with delayed toxicity within the 28 days prior to Study Day 1 (except for nitrosourea or mitomycin C treatments within 42 days prior to Study Day 1).
Chemotherapy regimens given continuously or on a weekly basis that Investigator believes to have a limited potential for delayed toxicity within 14 days prior to Study Day 1.
Use of an investigational anti-cancer drug within 42 days prior to Study Day 1.
Subject has symptomatic and/or untreated central nervous system metastases and/or intracranial hypertension.
Subject has a known history of an active and/or an uncontrolled infection with hepatitis A or hepatitis B.
Subject with a known history of a positive HIV status.
Subjects with pulmonary edema.
Subjects with respiratory failure
Subjects with severe emphysema, pulmonary emboli, pulmonary fibrosis or other conditions that cause pulmonary hypertension due to compromised pulmonary arterial vasculature.
Subjects with Raynaud's syndrome.
Subjects with a serious co-morbid medical condition.
If female, subject is pregnant and/or breastfeeding.
Any subject with congenital or acquired methemoglobinemia.
Any subject with a history of inherited anemia or hemoglobinopathy including but not limited to hereditary spherocytosis, hereditary elliptocytosis, hereditary ovalocytosis,

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Moores University of California San Diego Cancer Center	La Jolla	California	United States	92093
2	Sarah Cannon Research Institute	Nashville	Tennessee	United States	37203